While scientists have long known about axon degeneration, they haven’t had tools to stop it. Nura Bio’s lead drug candidate blocks a novel target associated with this damage to axons and the ...

Nura Bio Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced today ...

EPA Authors Describe Categorization Approach To PFAS To Identify Potential Candidates For Testing And Human Health ...

Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...

Dermavant Sciences Ltd. to Organon & Co. for $1.2 billion. The massive amount comprises an up-front $175 million payment, along with a potential $75 million regulatory milestone and up to $950 million ...

A promising new approach that could slow, stop or prevent nerves from dying may get its first test in patients next year.